Estuary Biotherapeutics launched on 16 October 2026 with a USD 93 million Series A led by RA Capital Management. Together with an earlier USD 10 million seed round, the company disclosed USD 103 million in committed financing. Estuary is developing locally delivered gene therapies for autosomal dominant polycystic kidney disease. Its two lead programmes target the PKD1 and PKD2 genetic subtypes, with funding intended to support clinical proof of concept and further platform development. The founding team includes CEO Wayne Sackett, Yale researchers Stefan Somlo and Michael Caplan, and gene therapy specialist Xavier Anguela. Clinical efficacy remains to be established.
Estuary Biotherapeutics launches with USD 93m Series A
RA Capital leads financing for targeted kidney gene therapies

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


